Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2007 1
2008 1
2009 2
2011 2
2012 1
2013 1
2014 4
2015 2
2016 1
2019 1
2020 3
2021 1
2022 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Combination antifungal therapy for invasive aspergillosis: a randomized trial.
Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, Kontoyiannis DP, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA. Marr KA, et al. Ann Intern Med. 2015 Jan 20;162(2):81-9. doi: 10.7326/M13-2508. Ann Intern Med. 2015. PMID: 25599346 Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of voriconazole and anidulafungin compared with voriconazole monotherapy for treatment of IA. DESIGN: Randomized, double-blind, placebo-controlled multicenter trial. ...CONCLUSION: Compared with voriconazole monotherapy, combina …
OBJECTIVE: To assess the safety and efficacy of voriconazole and anidulafungin compared with voriconazole monotherapy for treatment o …
Anidulafungin versus fluconazole for invasive candidiasis.
Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ; Anidulafungin Study Group. Reboli AC, et al. N Engl J Med. 2007 Jun 14;356(24):2472-82. doi: 10.1056/NEJMoa066906. N Engl J Med. 2007. PMID: 17568028 Free article. Clinical Trial.
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. ...The rate of death from all causes was …
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with flu …
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.
Reboli AC, Shorr AF, Rotstein C, Pappas PG, Kett DH, Schlamm HT, Reisman AL, Biswas P, Walsh TJ. Reboli AC, et al. BMC Infect Dis. 2011 Sep 30;11:261. doi: 10.1186/1471-2334-11-261. BMC Infect Dis. 2011. PMID: 21961941 Free PMC article. Clinical Trial.
In these patients, global response was significantly better for anidulafungin than fluconazole (81.1% vs 62.3%; 95% confidence interval [CI] for difference, 3.7-33.9). ...CONCLUSIONS: In patients with C. albicans infection, anidulafungin was more effective than fluc …
In these patients, global response was significantly better for anidulafungin than fluconazole (81.1% vs 62.3%; 95% confidence interv …
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Kett DH, et al. Crit Care. 2011;15(5):R253. doi: 10.1186/cc10514. Epub 2011 Oct 25. Crit Care. 2011. PMID: 22026929 Free PMC article. Clinical Trial.
The global response rate was 70.8% for anidulafungin and 54.1% for fluconazole (P = 0.03; 95% confidence interval (CI): 2.0 to 31.5); all-cause mortality was 10.1% versus 20.3% at 14 days (P = 0.08; 95% CI, -0.9 to 21.3) and was 20.2% versus 24.3% at 28 days (P = 0.57; 95% …
The global response rate was 70.8% for anidulafungin and 54.1% for fluconazole (P = 0.03; 95% confidence interval (CI): 2.0 to 31.5); …
Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Liu P, Mould DR. Liu P, et al. Antimicrob Agents Chemother. 2014 Aug;58(8):4718-26. doi: 10.1128/AAC.02808-13. Epub 2014 Jun 9. Antimicrob Agents Chemother. 2014. PMID: 24913161 Free PMC article. Clinical Trial.
To assess the pharmacokinetics (PK) of voriconazole and anidulafungin in patients with invasive aspergillosis (IA) in comparison with other populations, sparse PK data were obtained for 305 adults from a prospective phase 3 study comparing voriconazole and anidulafungin …
To assess the pharmacokinetics (PK) of voriconazole and anidulafungin in patients with invasive aspergillosis (IA) in comparison with …
Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.
Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Liu P, et al. Antimicrob Agents Chemother. 2013 Apr;57(4):1672-6. doi: 10.1128/AAC.02139-12. Epub 2013 Jan 18. Antimicrob Agents Chemother. 2013. PMID: 23335738 Free PMC article. Clinical Trial.
The pharmacokinetics of intravenous anidulafungin in adult intensive care unit (ICU) patients were assessed in this study and compared with historical data from a general patient population and healthy subjects. ...The average AUC(0-24) and Cmax in the general patient popu …
The pharmacokinetics of intravenous anidulafungin in adult intensive care unit (ICU) patients were assessed in this study and compare …
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. Krause DS, et al. Clin Infect Dis. 2004 Sep 15;39(6):770-5. doi: 10.1086/423378. Epub 2004 Aug 27. Clin Infect Dis. 2004. PMID: 15472806 Clinical Trial.
Anidulafungin is a novel antifungal agent of the echinocandin class. This randomized, double-blind, double-dummy study compared the efficacy and safety of intravenous anidulafungin to that of oral fluconazole in 601 patients with endoscopically and microbiologically …
Anidulafungin is a novel antifungal agent of the echinocandin class. This randomized, double-blind, double-dummy study compared the e …
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
Dowell JA, Schranz J, Baruch A, Foster G. Dowell JA, et al. J Clin Pharmacol. 2005 Dec;45(12):1373-82. doi: 10.1177/0091270005281234. J Clin Pharmacol. 2005. PMID: 16291712 Clinical Trial.
In a random sequence, 17 subjects received anidulafungin with placebo, voriconazole with placebo, and anidulafungin with voriconazole. Anidulafungin was administered intravenously: 200 mg on day 1, then 100 mg/d on days 2 through 4. ...
In a random sequence, 17 subjects received anidulafungin with placebo, voriconazole with placebo, and anidulafungin with voric …
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
De Rosa FG, Busca A, Capparella MR, Yan JL, Aram JA. De Rosa FG, et al. Clin Drug Investig. 2021 Jun;41(6):539-548. doi: 10.1007/s40261-021-01024-7. Epub 2021 Apr 23. Clin Drug Investig. 2021. PMID: 33891293 Free PMC article.
OBJECTIVES: Post hoc analysis of patient-level efficacy and safety data from six studies of anidulafungin (with similar protocols/endpoints) in adults with IC/candidemia summarized by past or recent diagnosis of solid tumors. ...The analysis included patients diagnosed wit …
OBJECTIVES: Post hoc analysis of patient-level efficacy and safety data from six studies of anidulafungin (with similar protocols/end …
Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.
Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL. Crandon JL, et al. Antimicrob Agents Chemother. 2009 Dec;53(12):5102-7. doi: 10.1128/AAC.01042-09. Epub 2009 Sep 21. Antimicrob Agents Chemother. 2009. PMID: 19770284 Free PMC article. Clinical Trial.
Voriconazole and anidulafungin in combination are being investigated for use for the treatment of pulmonary aspergillosis. ...In healthy adult volunteers, voriconazole achieved high levels of exposure in both ELF and AM, while anidulafungin predominantly concentrate …
Voriconazole and anidulafungin in combination are being investigated for use for the treatment of pulmonary aspergillosis. ...In heal …
23 results